Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
MEGA Stock Overview
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods.
Mega Lifesciences Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ฿54.00 |
52 Week High | ฿56.50 |
52 Week Low | ฿34.50 |
Beta | 0 |
1 Month Change | 13.09% |
3 Month Change | 24.86% |
1 Year Change | 47.95% |
3 Year Change | 60.00% |
5 Year Change | 100.00% |
Change since IPO | 153.52% |
Recent News & Updates
Shareholder Returns
MEGA | TH Pharmaceuticals | TH Market | |
---|---|---|---|
7D | 11.3% | -0.4% | -0.5% |
1Y | 47.9% | -18.6% | 4.4% |
Return vs Industry: MEGA exceeded the TH Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: MEGA exceeded the TH Market which returned 3.6% over the past year.
Price Volatility
MEGA volatility | |
---|---|
MEGA Average Weekly Movement | 5.2% |
Pharmaceuticals Industry Average Movement | 6.4% |
Market Average Movement | 5.1% |
10% most volatile stocks in TH Market | 9.8% |
10% least volatile stocks in TH Market | 2.6% |
Stable Share Price: MEGA is not significantly more volatile than the rest of TH stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MEGA's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | n/a | Vivek Dhawan | https://www.megawecare.com |
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods. The company operates through Brands, Distribution, and Original Equipment Manufacture segments. It provides various complementary medicines for bone and joint, children, diabetic, heart, herbal, liver and digestive, skin, slimming, and well-being care, as well as men’s and women’s care products and sports supplements; gastrointestinal and pain care OTC medicines; and prescription medicines in the areas of iron supplement, anticoagulant, diabetology, cardiology, dermatology, gastroenterology, neurology, pain, osteoporosis, respiratory, urology, oncology, and nephrology.
Mega Lifesciences Fundamentals Summary
MEGA fundamental statistics | |
---|---|
Market Cap | ฿47.08b |
Earnings (TTM) | ฿2.23b |
Revenue (TTM) | ฿14.72b |
21.1x
P/E Ratio3.2x
P/S RatioIs MEGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MEGA income statement (TTM) | |
---|---|
Revenue | ฿14.72b |
Cost of Revenue | ฿8.32b |
Gross Profit | ฿6.40b |
Other Expenses | ฿4.18b |
Earnings | ฿2.23b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
Earnings per share (EPS) | 2.55 |
Gross Margin | 43.49% |
Net Profit Margin | 15.13% |
Debt/Equity Ratio | 1.3% |
How did MEGA perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield54%
Payout RatioValuation
Is Mega Lifesciences undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
7.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MEGA (THB54) is trading below our estimate of fair value (THB58.12)
Significantly Below Fair Value: MEGA is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: MEGA is good value based on its PE Ratio (21.1x) compared to the Asian Pharmaceuticals industry average (23.1x).
PE vs Market: MEGA is poor value based on its PE Ratio (21.1x) compared to the TH market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: MEGA is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: MEGA is overvalued based on its PB Ratio (5.5x) compared to the XA Pharmaceuticals industry average (2.1x).
Future Growth
How is Mega Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
7.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEGA's forecast earnings growth (7.8% per year) is above the savings rate (2%).
Earnings vs Market: MEGA's earnings (7.8% per year) are forecast to grow slower than the TH market (18.6% per year).
High Growth Earnings: MEGA's earnings are forecast to grow, but not significantly.
Revenue vs Market: MEGA's revenue (7.7% per year) is forecast to grow slower than the TH market (10.4% per year).
High Growth Revenue: MEGA's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEGA's Return on Equity is forecast to be high in 3 years time (23.6%)
Past Performance
How has Mega Lifesciences performed over the past 5 years?
Past Performance Score
6/6Past Performance Score 6/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
14.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEGA has high quality earnings.
Growing Profit Margin: MEGA's current net profit margins (15.1%) are higher than last year (11%).
Past Earnings Growth Analysis
Earnings Trend: MEGA's earnings have grown by 14.3% per year over the past 5 years.
Accelerating Growth: MEGA's earnings growth over the past year (58.4%) exceeds its 5-year average (14.3% per year).
Earnings vs Industry: MEGA earnings growth over the past year (58.4%) exceeded the Pharmaceuticals industry 9.9%.
Return on Equity
High ROE: MEGA's Return on Equity (25.8%) is considered high.
Financial Health
How is Mega Lifesciences's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: MEGA's short term assets (THB9.6B) exceed its short term liabilities (THB4.6B).
Long Term Liabilities: MEGA's short term assets (THB9.6B) exceed its long term liabilities (THB395.5M).
Debt to Equity History and Analysis
Debt Level: MEGA has more cash than its total debt.
Reducing Debt: MEGA's debt to equity ratio has reduced from 9% to 1.3% over the past 5 years.
Debt Coverage: MEGA's debt is well covered by operating cash flow (1783.5%).
Interest Coverage: MEGA's interest payments on its debt are well covered by EBIT (187.8x coverage).
Balance Sheet
Dividend
What is Mega Lifesciences's current dividend yield, its reliability and sustainability?
Dividend Score
3/6Dividend Score 3/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
2.56%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MEGA's dividend (2.56%) is higher than the bottom 25% of dividend payers in the TH market (1.79%).
High Dividend: MEGA's dividend (2.56%) is low compared to the top 25% of dividend payers in the TH market (5.47%).
Stability and Growth of Payments
Stable Dividend: MEGA has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: MEGA's dividend payments have increased, but the company has only paid a dividend for 8 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (54%), MEGA's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (66.8%), MEGA's dividend payments are covered by cash flows.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.3yrs
Average board tenure
CEO
Vivek Dhawan (60 yo)
34.33yrs
Tenure
Mr. Vivek Dhawan has been the Chief Executive Officer of Mega Lifesciences Public Company Limited since 1988 and has been its Chief Coach since 2013. Mr. Dhawan started with Medicap and built Lupin Laborat...
Board Members
Experienced Board: MEGA's board of directors are considered experienced (9.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Mega Lifesciences Public Company Limited's employee growth, exchange listings and data sources
Key Information
- Name: Mega Lifesciences Public Company Limited
- Ticker: MEGA
- Exchange: SET
- Founded: 1982
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ฿47.081b
- Shares outstanding: 871.87m
- Website: https://www.megawecare.com
Location
- Mega Lifesciences Public Company Limited
- 909, Ample Tower
- 9th Floor
- Bangkok
- 10260
- Thailand
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/17 00:00 |
End of Day Share Price | 2022/05/17 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.